{"id":222089,"date":"2025-12-08T16:11:07","date_gmt":"2025-12-08T16:11:07","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/222089\/"},"modified":"2025-12-08T16:11:07","modified_gmt":"2025-12-08T16:11:07","slug":"blood-pressure-medication-recalled-may-be-contaminated-with-wrong-drug-kiro-7-news-seattle","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/222089\/","title":{"rendered":"Blood pressure medication recalled; may be contaminated with wrong drug \u2013 KIRO 7 News Seattle"},"content":{"rendered":"<p class=\"default__StyledText-sc-tl066j-0 gdrPeS body-paragraph\">The Food and Drug Administration has recalled a popular treatment for high blood pressure. <\/p>\n<p class=\"default__StyledText-sc-tl066j-0 gdrPeS body-paragraph\">The agency said that bottles of bisoprolol fumarate and hydrochlorothiazide tablets, under the brand name Ziac, may have been cross-contaminated with other drugs, <a href=\"https:\/\/www.usatoday.com\/story\/news\/health\/2025\/12\/06\/blood-pressure-drug-recall-ziac-cross-contamination\/87641330007\/\" target=\"_blank\" rel=\"noreferrer nofollow noopener\" title=\"https:\/\/www.usatoday.com\/story\/news\/health\/2025\/12\/06\/blood-pressure-drug-recall-ziac-cross-contamination\/87641330007\/\">USA Today<\/a> reported. <\/p>\n<p class=\"default__StyledText-sc-tl066j-0 gdrPeS body-paragraph\">The drugmaker said testing of reserve samples showed traces of ezetimibe, a cholesterol drug made by the same company. <\/p>\n<p class=\"default__StyledText-sc-tl066j-0 gdrPeS body-paragraph\">The recall affects tablets in dosages from 2.5 mg to 6.25 mg made by Madhya Pradesh in India for Glenmark Pharmaceuticals, <a href=\"https:\/\/www.usatoday.com\/story\/news\/health\/2025\/12\/06\/blood-pressure-drug-recall-ziac-cross-contamination\/87641330007\/\" target=\"_blank\" rel=\"noreferrer nofollow noopener\" title=\"https:\/\/www.usatoday.com\/story\/news\/health\/2025\/12\/06\/blood-pressure-drug-recall-ziac-cross-contamination\/87641330007\/\">USA Today<\/a> reported. <\/p>\n<p class=\"default__StyledText-sc-tl066j-0 gdrPeS body-paragraph\"><a href=\"https:\/\/thehill.com\/policy\/healthcare\/5636604-high-blood-pressure-medication-voluntarily-recalled-fda\/\" target=\"_blank\" rel=\"noreferrer nofollow noopener\" title=\"https:\/\/thehill.com\/policy\/healthcare\/5636604-high-blood-pressure-medication-voluntarily-recalled-fda\/\">The Hill<\/a> reported that more than 11,100 bottles have been recalled.<\/p>\n<p class=\"default__StyledText-sc-tl066j-0 gdrPeS body-paragraph\">The following pills have been recalled, according to <a href=\"https:\/\/www.usatoday.com\/story\/news\/health\/2025\/12\/06\/blood-pressure-drug-recall-ziac-cross-contamination\/87641330007\/\" target=\"_blank\" rel=\"noreferrer nofollow noopener\" title=\"https:\/\/www.usatoday.com\/story\/news\/health\/2025\/12\/06\/blood-pressure-drug-recall-ziac-cross-contamination\/87641330007\/\">USA Today<\/a>:<\/p>\n<ul>\n<li>30-tablet bottles, NDC-68462-878-30. Lot 17232401, expiration 11\/2025.<\/li>\n<li>100-tablet bottles, NDC-68462-878-01. Lot 17232401, expiration 11\/2025.<\/li>\n<li>500-tablet bottles, NDC-68462-878-05. Lots 17232401, exp. 11\/2025 and 17240974, expiration 05\/2026.<\/li>\n<\/ul>\n<p class=\"default__StyledText-sc-tl066j-0 gdrPeS body-paragraph\">The recall is a Class III, or &#8220;a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences,&#8221; according to the <a href=\"https:\/\/www.fda.gov\/safety\/industry-guidance-recalls\/recalls-background-and-definitions\" target=\"_blank\" rel=\"noreferrer nofollow noopener\" title=\"https:\/\/www.fda.gov\/safety\/industry-guidance-recalls\/recalls-background-and-definitions\">FDA<\/a>.<\/p>\n<p class=\"default__StyledText-sc-tl066j-0 gdrPeS body-paragraph\">Bisoprolol fumarate and hydrochlorothiazide are prescribed in combination. The first is a heart beta blocker, according to the <a href=\"https:\/\/www.mayoclinic.org\/drugs-supplements\/bisoprolol-and-hydrochlorothiazide-oral-route\/description\/drg-20071051\" target=\"_blank\" rel=\"noreferrer nofollow noopener\" title=\"https:\/\/www.mayoclinic.org\/drugs-supplements\/bisoprolol-and-hydrochlorothiazide-oral-route\/description\/drg-20071051\">Mayo Clinic<\/a> and allows it to beat normally. The second increases urination to remove sodium and water from a person. The medications also allow blood vessels to relax, lowering blood pressure and reducing the risk of heart attacks or strokes. <\/p>\n<p class=\"default__StyledText-sc-tl066j-0 gdrPeS body-paragraph body-copyright\">\u00a92025 Cox Media Group<\/p>\n","protected":false},"excerpt":{"rendered":"The Food and Drug Administration has recalled a popular treatment for high blood pressure. The agency said that&hellip;\n","protected":false},"author":2,"featured_media":221942,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[274],"tags":[87345,7549,119654,119655,79,34350,119656,2006,2593,19454,94504,184,18,119657,27127,57245,135,27129,19,2599,17,721,40326,1590,462,119658,14611,119659,6330,10243,119660,4586,119661,10144,23278,119662,1149,69073,119663,523,1057,119664,12443,2615,119665],"class_list":{"0":"post-222089","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-alert","9":"tag-announcement","10":"tag-blackboard","11":"tag-bullhorn","12":"tag-business","13":"tag-businessman","14":"tag-chalkboard","15":"tag-company","16":"tag-concept","17":"tag-customer","18":"tag-danger","19":"tag-economics","20":"tag-eire","21":"tag-endanger","22":"tag-hand","23":"tag-hazard","24":"tag-health","25":"tag-holding","26":"tag-ie","27":"tag-information","28":"tag-ireland","29":"tag-legal","30":"tag-liability","31":"tag-marketing","32":"tag-medication","33":"tag-megaphone","34":"tag-message","35":"tag-negligence","36":"tag-problem","37":"tag-product","38":"tag-product-recall","39":"tag-protection","40":"tag-quality","41":"tag-quality-control","42":"tag-recall","43":"tag-recalling","44":"tag-regulations","45":"tag-responsible","46":"tag-revoking","47":"tag-risk","48":"tag-safety","49":"tag-seller","50":"tag-sign","51":"tag-text","52":"tag-unsafe"},"share_on_mastodon":{"url":"","error":"Validation failed: Text character limit of 500 exceeded"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/222089","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=222089"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/222089\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/221942"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=222089"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=222089"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=222089"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}